1型糖尿病中血糖目标范围内时间恶化与微血管并发症的关联:5年真实世界研究
该5年纵向真实世界队列纳入246例成人1型糖尿病,评估CGM衍生血糖指标与微血管并发症复合终点的关联。结果显示TIR下降≥10%者并发症发生率33.3%,高于稳定组7.9%和上升≥10%组15.0%(p=0.011),ΔTIR独立关联结局,模型AUC 0.757-0.787。
要点
- TIR下降≥10%与5年微血管并发症风险升高相关(33.3% vs 7.9%)。
- ΔTIR在多变量分析中独立于年龄和基线TIR关联结局。
- CGM血糖指标联合年龄模型区分度可接受(AUC 0.757-0.787)。
核心结论
- CGM衍生血糖指标与1型糖尿病5年微血管并发症发生率相关,ΔTIR可能提供HbA1c之外的额外预后信息。
- 常规临床应用前需进一步验证。
研究设计与样本
- 纵向真实世界队列研究,随访5年,单中心三级转诊中心。
- 纳入246例成人1型糖尿病,中位年龄40(28-53)岁,糖尿病病程24(13-33)年。
- 无干预措施。
主要发现
- HbA1c从7.6%(59 mmol/mol)降至7.2%(55 mmol/mol),TIR(70-180 mg/dL)从50±14%升至61±15%。
- 所有CGM衍生指标(TIR、平均血糖、葡萄糖管理指标)均与复合终点相关。
- TIR下降≥10%者并发症发生率33.3%,稳定TIR者7.9%,TIR上升≥10%者15.0%(p=0.011)。
- 多变量分析校正年龄和基线TIR后,ΔTIR仍独立关联结局;BMI和收缩压不显著。
- 包含血糖指标和年龄的模型AUC为0.757-0.787。
关键数值与推荐
- 复合微血管终点包括:肾病(持续白蛋白尿≥20 µg/min、eGFR<60 mL/min/1.73 m2和/或因白蛋白尿使用RAAS抑制剂)、严重视网膜病变(增殖性视网膜病变、黄斑病变和/或失明)、周围神经病变(单丝评分<6/6和/或神经传导异常)。
临床怎么用
- 在1型糖尿病随访中可关注TIR的动态变化,TIR下降≥10%或提示微血管并发症风险升高。
- CGM血糖指标联合年龄可能辅助评估5年微血管并发症风险。
局限性
- 单中心真实世界队列,样本量246例,结果需外推验证。
- 作者指出常规临床实施前需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Beyond HbA1c, continuous glucose monitoring (CGM) is now widely used in clinical practice, providing more detailed information about glycemic control. However, its ability to predict long-term microvascular outcomes in type 1 diabetes remains unclear. OBJECTIVE: To evaluate the association between CGM-derived glucometrics and the 5-year incidence of microvascular complications, providing longitudinal real-world evidence in adults with type 1 diabetes. DESIGN: Longitudinal real-world cohort study with five-year follow-up. SETTING: Tertiary referral center. PARTICIPANTS: 246 adults with type 1 diabetes (median age 40 [28-53] years, diabetes duration 24 [13-33] years). INTERVENTION: No interventional treatment. MAIN OUTCOME MEASURE: Composite microvascular endpoint including nephropathy (persistent albuminuria ≥20 µg/min, eGFR <60 mL/min/1.73 m2, and/or RAAS inhibitor use for albuminuria), severe retinopathy (proliferative retinopathy, maculopathy, and/or blindness), and peripheral neuropathy (monofilament score <6/6 and/or abnormal nerve conduction). RESULTS: HbA1c decreased from 7.6% (59 mmol/mol) to 7.2% (55 mmol/mol), and time in range (TIR, 70-180 mg/dL) increased from 50 ± 14% to 61 ± 15%. All CGM-derived metrics (TIR, mean glucose, glucose management indicator) were associated with the composite endpoint. In this longitudinal real-world cohort, a ≥ 10% decrease in TIR was associated with higher complication rates (33.3%) compared with a stable TIR (7.9%) or ≥10% increase (15.0%) (p = 0.011). In multivariable analyses adjusted for age and baseline TIR, change in TIR (ΔTIR) remained independently associated with outcomes. BMI and systolic blood pressure were not significant. Models incorporating glucometrics and age showed acceptable discriminative performance (AUCs 0.757-0.787). CONCLUSIONS: CGM-derived glucometrics were associated with the 5-year incidence of microvascular complications in this real-world cohort, with ΔTIR potentially providing additional prognostic information beyond HbA1c. Further validation is needed before routine clinical implementation.
引用
- Sabbe A, Bochanen N, Van den Broucke A, et al. Association between worsening time in range and microvascular complications in type 1 diabetes: real-world 5-year study. J Clin Endocrinol Metab. 2026. PMID: 42745423. doi:10.1210/clinem/dgag380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。